{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-24-000018","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.544358+00:00","generated_at":"2026-06-06T23:23:07.749509+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio closes UK manufacturing, cuts 61% workforce; collaborator to conduct ITIL-306 feasibility studies","bullets":["Board approved closure of UK manufacturing and clinical operations; UK workforce reduced by ~61%.","Restructuring costs estimated up to $6.1M for severance and contract terminations; expect completion H1 2024.","No longer expects to report clinical data from ITIL-306-202 trial in 2024.","Entered agreement with collaborator for preclinical feasibility studies of ITIL-306 in NSCLC; potential IIT in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-24-000018","json":"https://secwatch.observer/filing/0001789769-24-000018.json","markdown":"https://secwatch.observer/filing/0001789769-24-000018.md","text":"https://secwatch.observer/filing/0001789769-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/0001789769-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/til-20240114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:23:07.749509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b4d01bc4a6fcc3785b1d23ffc2a9b440b509f3","claim":"Instil Bio, Inc. announced a restructuring with charges of up to $6.1 million affecting Manchester, UK manufacturing and clinical trial operations (approximately 61%).","evidence_excerpt":"report clinical data from the ITIL-306-202 clinical trial in 2024 . In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $6.1 million, including employee termination costs, including severance and other benefits, and contract termination costs. The charges that the Company expects to incur in connection with","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000018/0001789769-24-000018-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"up to $6.1 million"},{"label":"Affected area","value":"Manchester, UK manufacturing and clinical trial operations"},{"label":"Headcount","value":"approximately 61%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}